Fibromyalgia Assessment Screening Tool May Facilitate Diagnosis in Routine Care
Simple Fibromyalgia Assessment Screening Tool indices may facilitate the diagnosis of fibromyalgia in the routine care of patients with other rheumatic diseases.
Psoriatic Arthritis
High Prevalence of Neuropathic-Like Pain in Psoriatic Arthritis
The prevalence of neuropathic-like pain was found to be high in patients with psoriatic arthritis, a condition that may be associated with higher disease activity and fibromyalgia.
Main Factors Underlying Fatigue in PsA Identified
Inflammation, disease duration, and chronic pain were identified as the main factors underlying fatigue experienced by patients with psoriatic arthritis.
Apremilast Monotherapy Effective for DMARD-Naive Psoriatic Arthritis
The PALACE 4 trial found that apremilast monotherapy improved symptoms and was generally well-tolerated in DMARD-naive psoriatic arthritis.
Synovitis Detected by Ultrasound in Psoriatic Arthritis in Remission
Underlying synovitis and enthesitis may go undetected in clinical findings, but can be detected by power Doppler ultrasounds.
Psoriatic Arthritis Improved With Etanercept Therapy
Etanercept therapy reduces clinical markers of disease activity in patients with psoriatic arthritis while stabilizing cardiovascular disease risk factors over a period of 5 years.
A New Biomarker for Disease Activity in Psoriatic Arthritis?
Serum amyloid A levels were found to significantly correlate with C-reactive protein levels in psoriatic arthritis.
Treatment-Resistant Psoriatic Arthritis Improved by Ixekizumab
Ixekizumab benefits patients with treatment-resistant psoriatic arthritis when administered over a 2- or 4-week period.
Updated Psoriatic Arthritis Outcome Measures Offer Greater Inclusion of Patient Concerns
Outcome measurement tools for psoriatic arthritis have been updated by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis.
Remicade Biosimilar FDA-Approved
The FDA has approved Renflexis, the second approved biosimilar to Remicade.
Next post in Regulatory Issues
